214 related articles for article (PubMed ID: 14507635)
1. BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets.
Calhoun ES; Jones JB; Ashfaq R; Adsay V; Baker SJ; Valentine V; Hempen PM; Hilgers W; Yeo CJ; Hruban RH; Kern SE
Am J Pathol; 2003 Oct; 163(4):1255-60. PubMed ID: 14507635
[TBL] [Abstract][Full Text] [Related]
2. Fbxw7 contributes to tumor suppression by targeting multiple proteins for ubiquitin-dependent degradation.
Fujii Y; Yada M; Nishiyama M; Kamura T; Takahashi H; Tsunematsu R; Susaki E; Nakagawa T; Matsumoto A; Nakayama KI
Cancer Sci; 2006 Aug; 97(8):729-36. PubMed ID: 16863506
[TBL] [Abstract][Full Text] [Related]
3. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.
Kuhn E; Wu RC; Guan B; Wu G; Zhang J; Wang Y; Song L; Yuan X; Wei L; Roden RB; Kuo KT; Nakayama K; Clarke B; Shaw P; Olvera N; Kurman RJ; Levine DA; Wang TL; Shih IeM
J Natl Cancer Inst; 2012 Oct; 104(19):1503-13. PubMed ID: 22923510
[TBL] [Abstract][Full Text] [Related]
4. Loss of CDC4/FBXW7 in gastric carcinoma.
Milne AN; Leguit R; Corver WE; Morsink FH; Polak M; de Leng WW; Carvalho R; Offerhaus GJ
Cell Oncol; 2010; 32(5-6):347-59. PubMed ID: 20448329
[TBL] [Abstract][Full Text] [Related]
5. CCNE1 amplification is associated with aggressive potential in endometrioid endometrial carcinomas.
Nakayama K; Rahman MT; Rahman M; Nakamura K; Ishikawa M; Katagiri H; Sato E; Ishibashi T; Iida K; Ishikawa N; Kyo S
Int J Oncol; 2016 Feb; 48(2):506-16. PubMed ID: 26647729
[TBL] [Abstract][Full Text] [Related]
6. Infrequent mutations of Archipelago (hAGO, hCDC4, Fbw7) in primary ovarian cancer.
Kwak EL; Moberg KH; Wahrer DC; Quinn JE; Gilmore PM; Graham CA; Hariharan IK; Harkin DP; Haber DA; Bell DW
Gynecol Oncol; 2005 Jul; 98(1):124-8. PubMed ID: 15913747
[TBL] [Abstract][Full Text] [Related]
7. SCF(Fbxw7/hCdc4) targets cyclin E2 for ubiquitin-dependent proteolysis.
Klotz K; Cepeda D; Tan Y; Sun D; Sangfelt O; Spruck C
Exp Cell Res; 2009 Jul; 315(11):1832-9. PubMed ID: 19084516
[TBL] [Abstract][Full Text] [Related]
8. CDC4 mutations occur in a subset of colorectal cancers but are not predicted to cause loss of function and are not associated with chromosomal instability.
Kemp Z; Rowan A; Chambers W; Wortham N; Halford S; Sieber O; Mortensen N; von Herbay A; Gunther T; Ilyas M; Tomlinson I
Cancer Res; 2005 Dec; 65(24):11361-6. PubMed ID: 16357143
[TBL] [Abstract][Full Text] [Related]
9. Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma.
Sommerer F; Vieth M; Markwarth A; Röhrich K; Vomschloss S; May A; Ell C; Stolte M; Hengge UR; Wittekind C; Tannapfel A
Oncogene; 2004 Jan; 23(2):554-8. PubMed ID: 14724583
[TBL] [Abstract][Full Text] [Related]
10. Cyclin E gene (CCNE) amplification and hCDC4 mutations in endometrial carcinoma.
Cassia R; Moreno-Bueno G; RodrÃguez-Perales S; Hardisson D; Cigudosa JC; Palacios J
J Pathol; 2003 Dec; 201(4):589-95. PubMed ID: 14648662
[TBL] [Abstract][Full Text] [Related]
11. The FBXW7 beta-form is suppressed in human glioma cells.
Gu Z; Inomata K; Ishizawa K; Horii A
Biochem Biophys Res Commun; 2007 Mar; 354(4):992-8. PubMed ID: 17274947
[TBL] [Abstract][Full Text] [Related]
12. BRAF and K-ras gene mutations in human pancreatic cancers.
Ishimura N; Yamasawa K; Karim Rumi MA; Kadowaki Y; Ishihara S; Amano Y; Nio Y; Higami T; Kinoshita Y
Cancer Lett; 2003 Sep; 199(2):169-73. PubMed ID: 12969789
[TBL] [Abstract][Full Text] [Related]
13. Molecular and immunochemical analyses of RB1 and cyclin D1 in human ductal pancreatic carcinomas and cell lines.
Huang L; Lang D; Geradts J; Obara T; Klein-Szanto AJ; Lynch HT; Ruggeri BA
Mol Carcinog; 1996 Feb; 15(2):85-95. PubMed ID: 8599583
[TBL] [Abstract][Full Text] [Related]
14. Fbw7 isoform interaction contributes to cyclin E proteolysis.
Zhang W; Koepp DM
Mol Cancer Res; 2006 Dec; 4(12):935-43. PubMed ID: 17189384
[TBL] [Abstract][Full Text] [Related]
15. Structure of a Fbw7-Skp1-cyclin E complex: multisite-phosphorylated substrate recognition by SCF ubiquitin ligases.
Hao B; Oehlmann S; Sowa ME; Harper JW; Pavletich NP
Mol Cell; 2007 Apr; 26(1):131-43. PubMed ID: 17434132
[TBL] [Abstract][Full Text] [Related]
16. Somatic mutations of the CDC4 (FBXW7) gene in hereditary colorectal tumors.
Miyaki M; Yamaguchi T; Iijima T; Takahashi K; Matsumoto H; Mori T
Oncology; 2009; 76(6):430-4. PubMed ID: 19420964
[TBL] [Abstract][Full Text] [Related]
17. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
18. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma.
Caldas C; Hahn SA; da Costa LT; Redston MS; Schutte M; Seymour AB; Weinstein CL; Hruban RH; Yeo CJ; Kern SE
Nat Genet; 1994 Sep; 8(1):27-32. PubMed ID: 7726912
[TBL] [Abstract][Full Text] [Related]
19. FBXW7/hCDC4 is a general tumor suppressor in human cancer.
Akhoondi S; Sun D; von der Lehr N; Apostolidou S; Klotz K; Maljukova A; Cepeda D; Fiegl H; Dafou D; Marth C; Mueller-Holzner E; Corcoran M; Dagnell M; Nejad SZ; Nayer BN; Zali MR; Hansson J; Egyhazi S; Petersson F; Sangfelt P; Nordgren H; Grander D; Reed SI; Widschwendter M; Sangfelt O; Spruck C
Cancer Res; 2007 Oct; 67(19):9006-12. PubMed ID: 17909001
[TBL] [Abstract][Full Text] [Related]
20. Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene.
Mao JH; Perez-Losada J; Wu D; Delrosario R; Tsunematsu R; Nakayama KI; Brown K; Bryson S; Balmain A
Nature; 2004 Dec; 432(7018):775-9. PubMed ID: 15592418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
